Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 USD | +0.24% | -36.75% | -17.36% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.36% | 244M | |
+11.29% | 226B | |
+8.76% | 188B | |
+12.90% | 137B | |
+25.95% | 108B | |
+0.34% | 63.19B | |
+11.08% | 52.26B | |
+5.62% | 51B | |
+6.28% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07